Organization | Wuhan Institute of Biological Products Co., Ltd

Wuhan Institute of Biological Products Co., Ltd Report issue

Government Phase 1 Phase 2 Phase 3 Phase 4

Founded: Wuhan China (1950)

Organization Overview

First Clinical Trial

2012

NCT01676675

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Wuhan Institute of Biological Products Co., Ltd

Active Ingredients

Drugs in Phase 4 Trials (9)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (1 trial)

acellular pertussis vaccine (including diptheria and tetanus toxoids) (Tripedia) (1 trial)

covax-19 (3 trials)

ev71 vaccine (2 trials)

inactivated covid-19 vaccine (3 trials)

inactivated ev-a71 (1 trial)

inactivated influenza vaccine (3 trials)

live oral poliovirus type 1, 2 and 3 (Trivalent oral polio vaccine - Sabin) (1 trial)

split virion influenza vaccine (1 trial)

Drugs in Phase 3 Trials (3)

bibp omicron inactivated covid-19 vaccine (vero cell) (1 trial)

inactivated SARS-Cov-2 vaccine (1 trial)

omicron covid-19 vaccine (vero cell), inactivated (1 trial)

Drugs in Phase 2 Trials (1)

bgb-dxp604 (1 trial)

Drugs in Phase 1 Trials (1)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Enterovirus Infections (Phase 4)

Foot-and-Mouth Disease (Phase 4)

Hand, Foot and Mouth Disease (Phase 4)

Influenza, Human (Phase 4)

Influenza in Birds (Phase 1)

Mouth Diseases (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 15
# of Trial APIs: 14